News & Activities

GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer - ProBio

ProBio Accelerates Chimagen’s Global Market Expansion, Paving the Way for Innovative Antibody Therapy - ProBio

ProBio and UCI Therapeutics Sign a Strategic Cooperation MOU for Comprehensive Collaboration in Gene Delivery Technologies, Including Viral and Non-Viral Approaches - ProBio

ProBio Extends Congratulations to InnoBation Bio on MFDS Clearance of IBC101 Program - ProBio

ProBio Signs Collaboration Agreement with Cell Resources Corporation, a Subsidiary of Alfresa Holdings Corporation for Cell Therapy Development - ProBio

ProBio announces the appointment of Dr. Li Chen, as the Chief Executive Officer - ProBio

ProBio Congratulates TG ImmunoPharma on FDA Clearance of Clinical Trial for TGI-5 Monoclonal Antibody - ProBio

ProBio signs viral vector manufacturing MOU with Curocell for next-generation CAR-T therapy - ProBio

The MOU between ProBio and NuclixBio - ProBio

ProBio Partners with Epi Biotech to Advance Hair Loss Antibody Therapy - ProBio

ProBio Congratulates ABL Bio’s IND Clearance of ABL103 Program from MFDS - ProBio

Dx&Vx Signs Strategic Partnership with ProBio for Novel Drug Development - ProBio

ProBio Congratulates IMBiologics on FDA Clearance of IND Application for Innovative Bispecific Antibody Drug Project (IMB-101) - ProBio

ProBio and Comprehensive Cell Solutions, a Business Unit of the New York Blood Center Enterprises, Form a Pioneering Partnership to Expedite Cell and Gene Therapy Development and Manufacturing - ProBio

ProBio Congratulates Eutilex’s IND Clearance from MFDS - ProBio

ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA COVID-19 Vaccine Candidate - ProBio

A Joint Collaboration Between Bio Immunitas and ProBio Leads to the Development and Fast Track Manufacturing of A Novel Therapeutic Platform - ProBio

ProBio Congratulates Selecxine’s IND Clearance from MFDS - ProBio

Program CD47, provided the CMC service by ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp - ProBio

A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics，partners of ProBio, received IND clearance from NMPA for clinical trial - ProBio